Archives
-
nor-NOHA: Arginine Biology Beyond AML
2026-10-09
Explore how nor-NOHA acetate can serve as a mechanistic probe of arginase, nitric oxide, and tumor-cell behavior—without confusing established arginine biology with the distinct CD36-driven immune-escape pathway reported in AML. This evidence-focused perspective identifies testable connections, model limitations, and translational boundaries.
-
Lambda Protein Phosphatase in BMAL1 Research
2026-10-09
A source-grounded overview of how Lambda Protein Phosphatase may support phosphorylation analysis in BMAL1 phase-separation research, distinguishing supplier claims from findings in a 2026 circadian-biology study and outlining evidence strength, interpretation limits, and unresolved questions.
-
Cholecystokinin Octapeptide Ammonium: Evidence Map
2026-10-08
Cholecystokinin octapeptide ammonium is a sulfated brain–gut peptide ligand whose effects depend on receptor context, tissue, and endpoint. This evidence map connects CCK-8 ammonium with opioid modulation, neurobehavior, neuronal survival, immune signaling, and cardiac peptide secretion while separating established findings from plausible interpretation.
-
Angiotensin II in Vascular Remodeling Research
2026-10-08
Angiotensin II is a widely studied vasoactive peptide relevant to hypertension mechanisms, vascular smooth muscle biology and cardiovascular remodeling. This overview separates established peptide biology from a recent intracranial aneurysm study involving NPY1R, vascular smooth muscle cells and macrophages, while emphasizing evidence boundaries and the absence of direct evidence that Angiotensin II caused the reported aneurysm findings.
-
2-Thio-dCTP: Research Context and Evidence
2026-10-07
2-Thio-dCTP, also called 2-Thio-2'-deoxycytidine-5'-Triphosphate, is a modified cytidine triphosphate used as a research reagent for studying nucleotide incorporation, DNA polymerase selectivity, site-specific DNA modification and DNA–protein interactions. This overview separates the product’s stated molecular biology applications from findings in a 2026 study of SCP4 and histone H3T3 dephosphorylation, emphasizing what the evidence supports, what remains untested and where cross-domain interpretation would be premature.
-
N1-Methylpseudouridine in Cardiac mRNA Research
2026-10-07
N1-Methylpseudouridine offers a useful lens for studying how mRNA translation intersects with cardiac energy metabolism. This article interprets its potential research value alongside HEY2-dependent mitochondrial regulation while separating supplier claims from evidence established in cardiac models.
-
SW033291 and 15-PGDH: Research Context
2026-10-06
SW033291 is a small molecule 15-PGDH inhibitor used in research on prostaglandin E2 elevation, hematopoiesis, and tissue repair. This overview compares supplier-reported pharmacology with recent mouse evidence linking 15-PGDH inhibition to muscle regeneration during semaglutide-associated weight loss, while emphasizing provenance, translational limits, and the distinction between SW033291-specific evidence and findings involving an unspecified inhibitor.
-
Solanesol (B8776): Product Overview
2026-10-06
Solanesol is a supplier-described polyisoprenoid alcohol identified as C45H74O with a molecular weight of 631.09 g/mol. APExBIO lists it for conceptual research involving membrane-related processes, apoptosis research, DNA damage and repair studies, metabolic enzyme assays, and protease activity research. No matched research paper evidence was provided, so biological performance and application-specific suitability remain unestablished.
-
In Vitro Drug Response Metrics in Cancer Research
2026-10-05
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measures capture different relationships between growth inhibition and cell death. Its main contribution is a more precise framework for interpreting in vitro anticancer drug responses and for judging what a single viability endpoint can—and cannot—support.
-
Small-Biopsy Dye Marking in Surgical Pathology
2026-10-05
A 2023 study evaluated several dyes as visual markers for very small tissue biopsies during surgical pathology preparation. Its main contribution was to address tissue loss and recognition as pre-analytical problems, with hematoxylin emerging as the authors’ preferred marker because it improved visibility without reported interference in routine slide assessment.
-
One-step TUNEL Cy3 Kit: Evidence & Limits
2026-10-04
The One-step TUNEL Cy3 Apoptosis Detection Kit uses terminal deoxynucleotidyl transferase (TdT) labeling to visualize DNA strand breaks in cells and tissues. Its product-reported Cy3 signal supports fluorescence-based apoptosis research, but TUNEL positivity is not uniquely diagnostic of apoptosis and requires biological context.
-
SW033291: A Translational 15-PGDH Playbook
2026-10-02
SW033291 offers a mechanistically defined route from 15-PGDH inhibition to prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue repair. This thought-leadership article connects established hematopoietic and regeneration workflows with emerging evidence that 15-PGDH inhibition can improve muscle repair during semaglutide-associated weight loss, while distinguishing class-level findings from SW033291-specific validation.
-
CDC42 Polarity Controls Intestinal Stem Cell Fate
2026-10-01
Zhang et al. show that CDC42-dependent apical–basal polarity controls the intestinal stem cell to transit-amplifying cell transition through a YAP/TAZ–Ereg–EGFR–mTOR cascade. Genetic epistasis and pharmacological rescue experiments place epithelial architecture upstream of crypt proliferation and define a pathway that operates independently of canonical Wnt signaling under the tested conditions.
-
Z-VAD-FMK at the Ferroptosis–Apoptosis Boundary
2026-10-01
A mechanistic guide to using Z-VAD-FMK as an orthogonal tool for separating caspase-dependent apoptosis from ferroptotic membrane failure, with implications for cancer research, immune models, and translational study design.
-
SW033291: From Target Engagement to Tissue Repair
2026-09-30
SW033291 is a potent 15-PGDH inhibitor for connecting prostaglandin E2 elevation with hematopoiesis and tissue regeneration research. This article presents a phenotype-to-mechanism framework grounded in recent muscle-repair findings and practical assay decisions.